Welcome to our dedicated page for Redhill Biopharm SEC filings (Ticker: RDHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RedHill Biopharma Ltd. files foreign-issuer reports that document its specialty biopharmaceutical business, ADS capital structure and corporate governance. Recent Form 6-K reports incorporate press releases and meeting materials covering Talicia commercialization, RHB-204, RHB-102 and opaganib development disclosures, and clinical or regulatory updates tied to gastrointestinal, infectious-disease and oncology programs.
The company’s SEC record also includes shareholder-meeting notices and voting results for restricted share unit grants and authorized share-capital changes, as well as Nasdaq listing-compliance communications for its American depositary shares. Incorporation-by-reference language links these current reports to Form S-8 equity compensation registrations and Form F-3 shelf registration statements, reflecting recurring disclosure topics around financing capacity, equity plans, governance and material events.
RedHill Biopharma (RDHL) amended its Any Market Purchase Agreement with Alumni Capital to raise the beneficial ownership cap tied to Forward Purchase Notices from 4.99% to 9.99%. The agreement, originally signed on June 20, 2025, allows RedHill to sell up to $10,000,000 of ADSs to Alumni from time to time, at the company’s discretion.
Under a Forward Purchase Notice, Alumni may buy ADSs equal to the lesser of $500,000 or 30% of trading volume on the notice date, priced at the day’s lowest traded price multiplied by 96%. Other purchase types remain subject to a 4.99% ownership cap, with the option for the company to issue prefunded warrants instead of ADSs for Initial or Regular Purchase Notices. The amendment applies only to Forward Purchase Notices and does not change the overall program size.
RedHill Biopharma Ltd. announced a press release included in a Form 6-K describing a new ex‑US licensing deal for its H. pylori therapy Talicia and outlining the drug portfolio and public-health context for H. pylori treatment. The company states a new Middle East agreement includes upfront and milestone payments plus sales royalties totaling approximately $1.8M plus royalties. The release highlights Talicia as the leading branded H. pylori therapy among U.S. gastroenterologists, patent protection through 2042, and 8 years of U.S. market exclusivity under QIDP designation.
The filing summarizes H. pylori prevalence and risks: ~35 of U.S. adults (~1.6M treated annually), >50 globally, and up to ~80 in parts of the Middle East; H. pylori is linked to ~800,000 global deaths annually and ~27,000 U.S. gastric cancer diagnoses per year. The release notes rising antibiotic resistance and that current therapies fail in roughly 25-40 of patients, supporting the need for Talicia's rifabutin‑based regimen. The document also lists other pipeline assets and standard forward‑looking statements.
RedHill Biopharma Ltd. filed a Form 6-K attaching a press release that reports a New York Supreme Court appeal decision upholding a $10 million summary judgment in the company’s favor against Kukbo. The filing reiterates RedHill’s corporate registration details and lists recent and prior registration statements incorporated by reference. The document also summarizes RedHill’s clinical-stage pipeline, including opaganib (ABC294640) (multiple indications including GI-ARS, hospitalized COVID-19, prostate cancer), RHB-204 (planned Phase 2 for Crohn’s disease; Phase 3-stage for pulmonary NTM), RHB-107 (upamostat) (late-stage for non-hospitalized COVID-19 and other indications), and RHB-102 (positive Phase 2/3 results for GI indications; partnered with Hyloris Pharma). The filing contains no financial results or quantified impact of the judgment.
RedHill Biopharma Ltd. filed an amended Form 6-K to correct a prior submission from early September 2025. The company states that the only change is adding Exhibit 99.3, which contains management’s discussion and analysis of first half 2025 financial results.
The previously furnished press release on first half 2025 results (Exhibit 99.1) and the condensed consolidated interim unaudited financial information for the six months ended June 30, 2025 (Exhibit 99.2) are unchanged. The amended Form 6-K is also incorporated by reference into multiple existing Form S-8 and Form F-3 registration statements.
RedHill Biopharma Ltd. filed an amended Form 6-K to correct a prior submission from early September 2025. The company states that the only change is adding Exhibit 99.3, which contains management’s discussion and analysis of first half 2025 financial results.
The previously furnished press release on first half 2025 results (Exhibit 99.1) and the condensed consolidated interim unaudited financial information for the six months ended June 30, 2025 (Exhibit 99.2) are unchanged. The amended Form 6-K is also incorporated by reference into multiple existing Form S-8 and Form F-3 registration statements.
RedHill Biopharma Ltd. filed an amended Form 6-K to correct a prior submission from early September 2025. The company states that the only change is adding Exhibit 99.3, which contains management’s discussion and analysis of first half 2025 financial results.
The previously furnished press release on first half 2025 results (Exhibit 99.1) and the condensed consolidated interim unaudited financial information for the six months ended June 30, 2025 (Exhibit 99.2) are unchanged. The amended Form 6-K is also incorporated by reference into multiple existing Form S-8 and Form F-3 registration statements.
RedHill Biopharma Ltd. filed a Form 6-K as a foreign private issuer, providing investors with information on its first half of 2025 performance. The filing furnishes a press release on first half 2025 financial results and operational highlights, unaudited condensed consolidated interim financial information as of June 30, 2025, and related management discussion and analysis.
The 6-K is also incorporated by reference into multiple outstanding Form S-8 and Form F-3 registration statements, allowing the newly furnished information to form part of those securities offering documents.
RedHill Biopharma Ltd. announced that the New York Supreme Court awarded the company approximately $1.82 million in legal costs and expenses, in addition to a prior summary judgment award of approximately $8.25 million, with a 9% ongoing statutory interest applicable to both awards. The company also obtained a court-ordered attachment from Korea's Incheon District Court to seize Kukbo Co. Ltd.'s assets pending enforcement. Kukbo appealed the summary judgment on December 4, 2024, and briefing on that appeal is complete with oral argument tentatively scheduled for the September term; Kukbo may also appeal the legal-costs award. The release reiterates RedHill's clinical and commercial programs and includes standard forward-looking risk disclosures.
RedHill Biopharma reported receipt of its first ex-U.S. Talicia sales milestone, royalties and other payments totaling approximately $1.1 million following Talicia's first commercial launch outside the U.S. in 2024. Talicia is an FDA-approved, rifabutin-based therapy for H. pylori, a common infection affecting over 50% of adults worldwide and a major risk factor for gastric cancer and peptic ulcers. The product has QIDP designation providing up to eight years of U.S. exclusivity and patent protection through 2042. RedHill said Talicia showed up to 90% eradication in adherent patients in Phase 3 and contrasted this with lower effectiveness of clarithromycin-based regimens.
RedHill Biopharma disclosed it is not in compliance with Nasdaq Listing Rule 5550(b), which requires minimum stockholders' equity of $2,500,000. Nasdaq notified the Company of the deficiency on April 15, 2025 and on August 8, 2025 granted an extension giving the Company until October 13, 2025 to regain compliance.
The Company has submitted a plan to Nasdaq to restore compliance; if it does not meet the requirement by the extension date it may appeal to a Hearings Panel for additional time. The filing also notes that forward-looking statements about achieving compliance depend on market conditions and the satisfaction and closing of financing arrangements referenced in other filings.
RedHill Biopharma (Nasdaq: RDHL) filed a Form 6-K announcing positive FDA Type C meeting feedback for RHB-204, its next-generation, orally administered triple-antibiotic for Crohn’s disease (CD). The Agency agreed to a first-ever Phase 2 trial in MAP-positive CD patients, with co-primary endpoints of mucosal remission and MAP eradication. Use of rapid MAP diagnostics from two academic partners allows a smaller sample size, meaning lower cost and faster completion.
RHB-204 is protected by patents to 2041 and leverages Phase 3 data from predecessor RHB-104 that showed a 64 % efficacy improvement versus standard of care. Management plans to fund the study through non-dilutive grants/partnerships and pursue additional FDA designations (orphan, breakthrough, fast track) that could confer exclusivity and priority review vouchers. The Crohn’s market is forecast to expand from $13.6 bn in 2024 to $19 bn in 2033, creating significant commercial upside if the program succeeds. Key risks remain: trial execution, securing external funding, and eventual regulatory approval.